Temozolomide associated to gold nanoparticles promoted a synergic effect and apoptosis when exposed to melanoma cells
Source abstract
Abstract
Temozolomide (TMZ) is prescribed primarily because of its known ability to cross the blood-brain barrier, being a potentially chemotherapic drug for cancer treatment. However, it has dose-limiting hemotoxicity and rapid hydrolysis, which limits its anti-tumor efficacy. On the other hand, recent studies have shown that gold nanoparticles (GNPs) with their biocompatibility and cytotoxic potential in tumor cells can be combined with chemotherapy leading to an improvement in the existing treatment. Thus, this work aimed to evaluate the cytotoxic effects of TMZ associated with GNPs (T-GNPs) on B16F10 cells. Different GNPs were successfully synthetized, and the results showed that there was an electrostatic interaction between TMZ and GNPs, not changing their physicochemical properties. TMZ associated with GNPs exposed on B16F10 cells presented a cytotoxic effect even more pronounced than free TMZ. In addition, different T-GNPs did not induced cytotoxic effect on non-tumor cells (NIH3T3 and red blood cells). A synergism between TMZ and GNPs was observed, inducing B16F10 cell death by apoptosis.
Source: expertdata · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Gold and Silver Nanoparticles Synthesis and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (47)
Show source-provided references
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–24910.3322/caac.21660 ↗
2. Domingues B, Lopes J, Soares P, Populo H (2018) Melanoma treatment in review. ImmunoTargets Ther 7:35–4910.2147/ITT.S134842 ↗
3. Leonardi GC, Falzone L, Salemi R, Zanghì A, Spandidos DA, Mccubrey JA et al (2018) Cutaneous melanoma: from pathogenesis to therapy (Review). Int J Oncol 52:1071–1080
4. Testori A, Rutkowski P, Marsden J, Bastholt L, Chiarion-Sileni V, Hauschild A et al (2009) Surgery and radiotherapy in the treatment of cutaneous melanoma. Ann Oncol 20:vi22 (Oxford University Press; [cited 2022 Jun 23]. Available from: /pmc/articles/PMC2712595/)10.1093/annonc/mdp257 ↗
5. Strojan P (2010) Role of radiotherapy in melanoma management. Radiol Oncol 44:1 (De Gruyter; [cited 2022 Jun 23];44:1. Available from: /pmc/articles/PMC3423668/)10.2478/v10019-010-0008-x ↗
6. Pflugfelder A, Kochs C, Blum A, Capellaro M, Czeschik C, Dettenborn T et al (2013) Malignes melanom S3-leitlinie “Diagnostik, therapie und nachsorge des melanoms.” JDDG - J Ger Soc Dermatol 11:1–126
7. Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Spatz A, Grob JJ, Malvehy J, Newton-Bishop J, Stratigos A, Pehamberger H, Eggermont A (2010) Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer 46(2):270–83. https://doi.org/10.1016/j.ejca.2009.10.03210.1016/j.ejca.2009.10.032 ↗
8. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466. https://doi.org/10.1016/S1470-2045(09)70025-7 (Elsevier Ltd)10.1016/S1470-2045(09)70025-7 ↗
9. Clemente N, Ferrara B, Gigliotti CL, Boggio E, Capucchio MT, Biasibetti E et al (2018) Solid lipid nanoparticles carrying temozolomide for melanoma treatment. Preliminary in vitro and in vivo studies. Int J Mol Sci 19:25510.3390/ijms19020255 ↗
10. Zhang JFG, Stevens MD, Bradshaw T (2012) Temozolomide: mechanisms of action, repair and resistance. Curr Mol Pharmacol 5:102–11410.2174/1874467211205010102 ↗
11. Ryabaya OO, Inshakov AN, Egorova AV, Emelyanova MA, Nasedkina TV, Zasedatelev AS et al (2016) Autophagy inhibitors chloroquine and LY294002 enhance temozolomide cytotoxicity on cutaneous melanoma cell lines in vitro. Anticancer Drugs 28:307–31510.1097/CAD.0000000000000463 ↗
12. Hirose Y, Berger MS, Pieper RO (2001) p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 61:1957–1963
13. Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y, Kondo S (2004) Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ 11:448–45710.1038/sj.cdd.4401359 ↗
14. Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN et al (2009) Phase II trial of temozolomide plus O6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol 27:1262–126710.1200/JCO.2008.18.8417 ↗
15. Bai X, Wang Y, Song Z, Feng Y, Chen Y, Zhang D et al (2020) The basic properties of gold nanoparticles and their applications in tumor diagnosis and treatment. Int J Mol Sci 21:248010.3390/ijms21072480 ↗
16. de Pinho RA, Haupenthal DPS, Feuser PE, Thirupathi A, Silveira PCL (2022) Gold Nanoparticle-based therapy for muscle inflammation and oxidative stress. J Inflamm Res 15:3219–323410.2147/JIR.S327292 ↗
17. Li H, Jin H, Wan W, Wu C, Wei L (2018) Cancer nanomedicine: mechanisms, obstacles and strategies. Nanomedicine. 13:1639–165610.2217/nnm-2018-0007 ↗
18. Sztandera K, Gorzkiewicz M, Klajnert-Maculewicz B (2019) Gold nanoparticles in cancer treatment. Mol Pharm 16:1–2310.1021/acs.molpharmaceut.8b00810 ↗
19. Mukherjee P, Bhattacharya R, Wang P, Wang L, Basu S, Nagy JA et al (2005) Antiangiogenic properties of gold nanoparticles. Clin Cancer Res 11:3530–353410.1158/1078-0432.CCR-04-2482 ↗
20. Della Vechia IC, Steiner BT, Freitas ML, Giulia D, Santos P, Fidelis NC et al (2020) Comparative cytotoxic effect of citrate-capped gold nanoparticles with different sizes on noncancerous and cancerous cell lines. J Nanopart Res 23:133. https://doi.org/10.1007/s11051-020-04839-1 ([cited 2020 May 19])10.1007/s11051-020-04839-1 ↗
21. Chou TC (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70(2):440–44610.1158/0008-5472.CAN-09-1947 ↗
22. Orza A, Soriţǎu O, Tomuleasa C, Olenic L, Florea A, Pana O et al (2013) Reversing chemoresistance of malignant glioma stem cells using gold nanoparticles. Int J Nanomedicine 8:689–70210.2147/IJN.S37481 ↗
23. Feuser PE, Cordeiro AP, de Bem SG, Borges Corrêa MEA, Lock Silveira PC, Sayer C et al (2021) Co-encapsulation of sodium diethyldithiocarbamate (DETC) and zinc phthalocyanine (ZnPc) in liposomes promotes increases phototoxic activity against (MDA-MB 231) human breast cancer cells. Colloids Surf B: Biointerfaces 197:111434 (Elsevier)10.1016/j.colsurfb.2020.111434 ↗
24. Della Vechia IC, Steiner BT, Freitas ML, dos Santos Pedroso Fidelis G, Galvani NC, Ronchi JM et al (2020) Comparative cytotoxic effect of citrate-capped gold nanoparticles with different sizes on noncancerous and cancerous cell lines. J Nanopart Res 22:1–1110.1007/s11051-019-4718-8 ↗
25. Fan L, Wang W, Wang Z, Zhao M (2021) Gold nanoparticles enhance antibody effect through direct cancer cell cytotoxicity by differential regulation of phagocytosis. Nat Commun 12:1–13 (Springer US)10.1038/s41467-020-20314-w ↗
26. Cordeiro AP, Feuser PE, Figueiredo PG, da Cunha ES, Martinez GR, Machado-de-Ávila RA et al (2021) In vitro synergic activity of diethyldithiocarbamate and 4-nitrochalcone loaded in beeswax nanoparticles against melanoma (B16F10) cells. Mater Sci Eng C 120:11165110.1016/j.msec.2020.111651 ↗
27. González-López MA, Gutiérrez-Cárdenas EM, Sánchez-Cruz C, Hernández-Paz JF, Pérez I, Olivares-Trejo JJ et al (2020) Reducing the effective dose of cisplatin using gold nanoparticles as carriers. Cancer Nanotechnol 11:1–15. https://doi.org/10.1186/s12645-020-00060-w (Springer Vienna)10.1186/s12645-020-00060-w ↗
28. Mateo D, Morales P, Ávalos A, Haza AI (2015) Comparative cytotoxicity evaluation of different size gold nanoparticles in human dermal fibroblasts. J Exp Nanosci 10:1401–141710.1080/17458080.2015.1014934 ↗
29. Mohan JC, Praveen G, Chennazhi KP, Jayakumar R, Nair SV (2013) Functionalised gold nanoparticles for selective induction of in vitro apoptosis among human cancer cell lines. J Exp Nanosci 8:32–4510.1080/17458080.2011.557841 ↗
30. Tran M, DePenning R, Turner M, Padalkar S (2016) Effect of citrate ratio and temperature on gold nanoparticle size and morphology. Mater Res Express 3:1–10. https://doi.org/10.1088/2053-1591/3/10/105027 (IOP Publishing)10.1088/2053-1591/3/10/105027 ↗
31. Elbialy NS, Fathy MM, Khalil WM (2015) Doxorubicin loaded magnetic gold nanoparticles for in vivo targeted drug delivery. Int J Pharm 490:190–199. https://doi.org/10.1016/j.ijpharm.2015.05.032 (Elsevier B.V)10.1016/j.ijpharm.2015.05.032 ↗
32. Afzalipour R, Khoei S, Khoee S, Shirvalilou S, Jamali Raoufi N, Motevalian M et al (2019) Dual-targeting temozolomide loaded in folate-conjugated magnetic triblock copolymer nanoparticles to improve the therapeutic efficiency of rat brain gliomas. ACS Biomater Sci Eng 5:6000–601110.1021/acsbiomaterials.9b00856 ↗
33. Wang W, Ding X, Xu Q, Wang J, Wang L, Lou X (2016) Zeta-potential data reliability of gold nanoparticle biomolecular conjugates and its application in sensitive quantification of surface absorbed protein. Colloids Surf B: Biointerfaces 148:541–548 (Elsevier B.V.)10.1016/j.colsurfb.2016.09.021 ↗
34. Wang L, Tang S, Yu Y, Lv Y, Wang A, Yan X et al (2021) Intranasal delivery of temozolomide-conjugated gold nanoparticles functionalized with anti-EphA3 for glioblastoma targeting. Mol Pharm 18:915–927 ([cited 2022 Jun 3]. American Chemical Society. Available from: https://pubs.acs.org/doi/full/10.1021/acs.molpharmaceut.0c00911)10.1021/acs.molpharmaceut.0c00911 ↗
35. dos Santos Haupenthal DP, Zortea D, Zaccaron RP, de Bem SG, Corrêa MEAB, Mendes C et al (2020) Effects of phonophoresis with diclofenac linked gold nanoparticles in model of traumatic muscle injury. Mater Sci Eng C 110:110681 (Elsevier Ltd)10.1016/j.msec.2020.110681 ↗
36. Cseh AM, Fabian Z, Quintana-Cabrera R, Szabo A, Eros K, Soriano ME et al (2019) PARP inhibitor PJ34 protects mitochondria and induces DNA-damage mediated apoptosis in combination with cisplatin or temozolomide in B16F10 melanoma cells. Front Physiol 10:1–1510.3389/fphys.2019.00538 ↗
37. Babaei A, Mousavi SM, Ghasemi M, Pirbonyeh N, Soleimani M, Moattari A (2021) Gold nanoparticles show potential in vitro antiviral and anticancer activity. Life Sci 284:119652. https://doi.org/10.1016/j.lfs.2021.119652 (Life Sciences)10.1016/j.lfs.2021.119652 ↗
38. Desai N, Momin M, Khan T, Gharat S, Ningthoujam RS, Omri A (2021) Metallic nanoparticles as drug delivery system for the treatment of cancer. Expert Opin Drug Deliv 18:1261–1290. https://doi.org/10.1080/17425247.2021.1912008 (Taylor & Francis)10.1080/17425247.2021.1912008 ↗
39. Rafiei S, Rezatofighi SE, Ardakani MR, Rastegarzadeh S (2016) Gold nanoparticles impair foot-and-mouth disease virus replication. IEEE Trans Nanobiosci 15:34–4010.1109/TNB.2015.2508718 ↗
40. Uggioni MLR, Feuser PE, Possato JC, de Melo ME, De Pieri E, Cercena R et al (2022) Synergic effect of paclitaxel and cisplatin associated with gold nanoparticles on HeLa cervical cells. Gold Bull 2021:1–11 (Springer; [cited 2022 Jan 26]. Available from: https://link.springer.com/article/10.1007/s13404-021-00305-5)
41. Fadera S, Chen PY, Liu HL, Lee IC (2021) Induction therapy of retinoic acid with a temozolomide-loaded gold nanoparticle-associated ultrasound effect on glioblastoma cancer stem-like colonies. ACS Appl Mater Interfaces 13:32845–3285510.1021/acsami.1c09634 ↗
42. Gialluca VD, de Lima VGP, Caixeta A, Castilho ML, Raniero LJ (2021) Gold nanoparticles associated with temozolomide for glioblastoma multiforme treatment. Res Soc Dev 10:e146101119406 (Research, Society and Development; [cited 2022 Jun 3]. Available from: https://rsdjournal.org/index.php/rsd/article/view/19406)10.33448/rsd-v10i11.19406 ↗
43. Shojaei S, Koleini N, Samiei E, Aghaei M, Cole LK, Alizadeh J et al (2020) Simvastatin increases temozolomide-induced cell death by targeting the fusion of autophagosomes and lysosomes. FEBS J 287:1005–1034 (John Wiley & Sons, Ltd; [cited 2021 Dec 3];Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/febs.15069)10.1111/febs.15069 ↗
44. Ouyang Z, Peng D, Dhakal DP (2013) Risk factors for hematological toxicity of chemotherapy for bone and soft tissue sarcoma. Oncol Lett 5:1736–1740. https://doi.org/10.3892/ol.2013.123410.3892/ol.2013.1234 ↗
45. Fornaguera C, Calderó G, Mitjans M, Vinardell MP, Solans C, Vauthier C (2015) Interactions of PLGA nanoparticles with blood components: protein adsorption, coagulation, activation of the complement system and hemolysis studies. Nanoscale. 7:6045–605810.1039/C5NR00733J ↗
46. Yang X, Yang M, Pang B, Vara M, Xia Y (2015) Gold nanomaterials at work in biomedicine. Chem Rev 115:10410–1048810.1021/acs.chemrev.5b00193 ↗
47. Vlachostergios PJ, Papandreou CN (2015) Efficacy of low dose temozolomide in combination with bortezomib in U87 glioma cells: a flow cytometric analysis. Arch Med Sci 11:307–31010.5114/aoms.2013.36919 ↗